Gilead Sciences, Inc. (GILD) Stock Price, News, Analysis

Technical Score (1D)

BUY

News Sentiment

BEARISH

Gilead’s Biktarvy patent is set to expire soon, threatening to open the door for generic competition. The loss of exclusive pricing on this blockbuster HIV drug could reduce the company’s top‑line revenue over the next few weeks. Meanwhile, rivals such as Merck, Pfizer, and GSK are rapidly advancing next‑generation antiretrovirals that promise lower costs and improved efficacy. If any of those competitors launch a comparable therapy before the patent expires, Gilead may have to lower prices or lose market share. The company’s ability to maintain earnings will therefore hinge on how quickly its own pipeline candidates reach the clinic and how it positions Biktarvy’s pricing. Investors should monitor any regulatory filings or clinical data releases for Gilead’s upcoming candidates, as a positive milestone could offset the patent risk. Watch for pricing announcements or partnership deals that could signal Gilead’s strategy to defend its revenue base. Additionally, keep an eye on competitor launch dates, as a new product introduction could accelerate the erosion of Gilead’s market share. In the next 1–10 trading days, the market will likely react to any early indications of pipeline progress or pricing adjustments that could mitigate the impact of the patent expiration.

GILD|Company Info

Sector

Healthcare

Industry

Drug Manufacturers - General

Exchange

NMS

Country

United States

Website

gilead.com

Symbol

GILD

Description

Gilead Sciences is a biopharmaceutical company focused on discovering, developing, and marketing medicines to address significant unmet medical needs globally. The company's core business centers on treatments for viral diseases, including HIV/AIDS and hepatitis, with a portfolio of established therapies such as Biktarvy, Genvoya, and Epclusa. Beyond virology, Gilead offers oncology products like Yescarta and Trodelvy, as well as treatments for pulmonary arterial hypertension and invasive fungal infections. Gilead leverages strategic collaborations with other pharmaceutical and biotechnology companies, including Arcus Biosciences and Merck, to expand its research and development capabilities and pipeline of potential future therapies. Founded in 1987, the company is headquartered in Foster City, California.

GILD|Earnings Snapshot

Earnings Summary

Gilead Sciences, headquartered in Foster City, California, is a biopharmaceutical company that develops and markets medicines for viral diseases such as HIV/AIDS and hepatitis, while also expanding into oncology and other therapeutic areas. In the highly competitive drug‑manufacturing sector, Gilead’s portfolio of established antivirals and newer oncology products positions it as a key player in both legacy and emerging markets. In the most recent quarters, the company reported a 3.2% increase in earnings per share (EPS) from Q4 2024 (1.90 vs. 1.70) to Q1 2025 (1.81 vs. 1.78), and a 6.4% rise in EPS from Q2 2025 (2.01 vs. 1.96) to Q3 2025 (2.47 vs. 2.14), while revenue grew from $7.08 billion to $7.77 billion, reflecting a 9.8% YoY lift. However, Q4 2025 saw a 25% decline in EPS (1.86 vs. 2.47) despite a modest 2% revenue uptick to $7.93 billion, and Q1 2026 reversed the EPS trend with a 9% increase to $2.03 vs. 1.96, but revenue fell 12% to $6.96 billion. Across six quarters, Gilead has beaten analyst estimates in five instances, missing only in Q4 2025, and has maintained a consistent pattern of EPS beats amid fluctuating revenue growth. Historically, the company has shown steady YoY revenue expansion in the 2024‑2025 period, with EPS growth outpacing revenue in the first three quarters of 2025, but a recent dip in Q4 2025 and Q1 2026 signals potential margin pressure. Recent news highlights include the Q1 earnings beat driven by HIV and COVID‑19 product lines, the FDA acceptance of a supplemental NDA for a 300 mg Yeztugo tablet, the first‑line approval of Trodelvy for triple‑negative breast cancer, and a partnership to deploy a mobile leukapheresis center for CAR‑T therapy, all of which could broaden Gilead’s revenue streams. Investors should watch for the Q2 guidance on pipeline milestones and pricing rulings, monitor early sales data for Yeztugo and Trodelvy, and track the rollout progress of the mobile CAR‑T program to gauge the company’s ability to sustain earnings momentum.

Read full report

EPS

EstBeatMiss

Qtr	Est	Actual	+/−
Q2'26	$-7.30	-	-
Q1'26	$1.95	$2.03	+4.0%
Q4'25	$1.98	$1.86	-6.2%
Q3'25	$2.14	$2.47	+15.7%
Q2'25	$1.96	$2.01	+2.7%
Q1'25	$1.78	$1.81	+1.9%

Revenue

EstBeatMiss

Qtr	Est	Actual	+/−
Q2'26	$7.5B	-	-
Q1'26	$7.1B	$7.0B	-1.3%
Q4'25	$6.9B	$7.9B	+14.1%
Q3'25	-	$7.8B	-
Q2'25	-	$7.1B	-
Q1'25	-	$6.7B	-

Full Earnings BreakdownEstimates, actuals, guidance, and historical context

→

Market Data

GILD Stock Snapshot

GILD is currently trading at $134.30, giving Gilead Sciences, Inc. a market cap of 167.38B and a P/E ratio of 18.2. Today's range spans $134.09–$140.61, with shares opening at $137.75 and moving up $0.02 (0.0%) from the prior close. DailyIQ's technical score sits at 68/100 (BUY) with a news sentiment reading of 40/100.

Over the past year GILD has traded between $107.75 and $157.29 - the current price is +24.6% off the 52-week low and -14.6% from the high. 39 analysts cover the stock with a Buy consensus and a mean 12-month target of $158.30 (range $120.00–$180.00), implying upside of +17.9%.

Relative strength is the story for Gilead Sciences, Inc. (GILD) in Healthcare right now. Technical score 68/100 (BUY), sentiment bearish at 40/100, price $134.30 (in the middle of its 52-week range). The current P/E ratio stands at 18.2. The 167.38B market cap keeps this name on institutional screens, and the bullish setup means sector rotation inflows from Healthcare have a natural landing spot here. Annual range: $107.75–$157.29.

What makes GILD's BUY setup (68/100) particularly actionable at 167.38B in Healthcare capitalization is the scale-to-move ratio: large enough to feature on institutional mandates but not so large that the percentage upside is already compressed by index inertia. At $134.30 (in the middle of its 52-week range in $107.75–$157.29), with sentiment running bearish at 40/100, the setup rewards conviction-sized positioning more than it does speculative small bets.

News Sentiment Analysis

Sentiment gathered from recent headlines

40/100

Strong NegativeNeutralStrong Positive

BEARISH

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

10+ articles

What did this article say?

Gilead Sciences (GILD) slipped 1.48% to $134.28, lagging the broader market. The company’s EPS is projected at –$7.09, a 452.74% decline YoY, while revenue is expected to hit $7.37 billion, up 4.02% YoY. Analysts have issued upward revisions to estimates, reflecting some optimism about short‑term trends. Traders should watch the upcoming earnings report for any changes to guidance.

What did this article say?

Gilead’s core HIV business faces pressure as Biktarvy’s patent protection ends in 2025, potentially eroding its revenue base. The company’s ability to sustain growth will hinge on launching next‑generation antiretrovirals or securing licensing agreements. Investors should monitor the timing of the patent expiry and any regulatory approvals for new HIV therapies that could offset the loss.

What did this article say?

No summary available yet for this article.

What did this article say?

Gilead Sciences (GILD) has become a top focus for Zacks.com users, indicating heightened investor interest. The stock’s visibility suggests analysts are scrutinizing its recent performance and future catalysts. Traders should assess how this attention may influence short‑term volatility and potential support levels. Understanding the drivers behind the increased coverage can help anticipate market reactions.

What did this article say?

Gilead Sciences reported Q1 earnings that surpassed analyst expectations, driven largely by its HIV and COVID‑19 product lines. Revenue growth was supported by the launch of single‑tablet regimens and ongoing precision‑medicine initiatives. The company faces headwinds from increasing drug‑pricing scrutiny and regulatory uncertainty, which could temper future growth. Investors should watch upcoming guidance on the HIV pipeline and any regulatory rulings that may affect pricing.

What did this article say?

Gilead Sciences is moving beyond its core HIV portfolio with four new drug launches slated for this year. The expansion signals a strategic pivot toward broader therapeutic areas, potentially diversifying revenue streams. Investors have historically viewed GILD as an HIV-focused company, but these approvals could reshape the market narrative. The company’s pipeline includes treatments for hepatitis B, hepatitis C, and other viral infections. The timing of these launches aligns with regulatory approvals expected in Q3 and Q4. This shift may attract new institutional interest and broaden GILD’s investor base.

What did this article say?

Gilead Sciences (GILD) fell 3.72% to $129.83, lagging the broader market despite a 7.13% monthly gain. The company’s upcoming earnings are expected to report a negative EPS of $7.13, a sharp decline from the prior year, while revenue is projected to rise 3.98% to $7.36 billion. Analysts are closely watching the earnings release for any shifts in guidance or cost‑control measures. The market reaction reflects uncertainty around Gilead’s profitability outlook amid a modest revenue uptick.

What did this article say?

Gilead’s 5‑year return of ~140% underpins a valuation that sits between cheap and expensive. Recent regulatory approvals for Trodelvy and Yeztugo add upside potential, but execution risk around these therapies and future clinical outcomes could temper investor willingness to pay. The company’s cash‑flow profile remains a key factor in justifying the current price. Traders should monitor upcoming data on Trodelvy’s sales trajectory and any new approvals for Yeztugo.

What did this article say?

Gilead Sciences (GILD) received FDA approval for Trodelvy as first‑line therapy for advanced triple‑negative breast cancer, a move that expands its oncology portfolio. European regulators granted similar approval, broadening access for eligible patients in the EU. The company partnered with BBG Advanced Therapies to deploy a mobile center delivering Kite CAR‑T cell therapies across Texas, enhancing regional access. These developments strengthen GILD’s position in oncology and cell therapy, potentially boosting future revenue streams.

What did this article say?

Gilead Sciences (GILD) has been removed from several Russell growth‑oriented indexes, a technical change that could alter how index‑tracking funds hold the stock and influence portfolio construction. The removal follows a strong short‑term price run, with a 7.82% return over the past week and an 11.69% year‑to‑date gain, while long‑term shareholder returns remain robust. Investors are now evaluating whether the recent price appreciation already reflects GILD’s fundamentals or if the current valuation still offers upside potential.

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

10+ articles

What did this article say?

No summary available yet for this article.

What did this article say?

GILD·Gilead Sciences, Inc.

EPS

Revenue

GILD Stock Snapshot

News Sentiment Analysis

Recent News Coverage

Discover More

News Sentiment Analysis

Recent News Coverage

Discover More